New Integrated Platform Streamlines, Guides Genomic Analysis for Clinical Trials
Omicia, Inc. today announced that Omicia’s clinical next-generation sequencing (NGS) interpretation software will be used by Laboratory Corporation of America® Holdings (LabCorp®) for its clinical trials sequencing services. LabCorp’s broad menu of testing services, combined with Omicia’s flexible, powerful, and easy-to-use genome analysis platform, will allow the companies to provide a comprehensive suite of expert tools and services for incorporating genomic data into clinical trials. Omicia’s software allows users to quickly and easily annotate genomes, analyze variant data, and generate customized clinical reports for individual patients and research projects across a broad range of disease states and clinical trial designs. Customers can also store, analyze, and manage their clinical trial data within a highly secure environment.
“Demand for well annotated and meaningful biomarker data to guide clinical trial design and execution is on the rise,” said Mike Aicher, Omicia CEO. “By integrating our breakthrough Opal genomic interpretation software with LabCorp’s clinical trials sequencing services into a complete and comprehensive solution, the analysis of genomic data can be easily and effectively integrated within clinical trials.”
The Omicia/LabCorp collaboration addresses the growing demand for NGS-derived biomarker data. This effort also highlights LabCorp’s continued focus on biomarker development to support clinical trial activities. The collaboration will enable customers of both companies to easily integrate NGS data into clinical trials and carry out studies quickly, efficiently, and affordably.
Omicia provides a state-of-the-art genome analysis software suite using proprietary algorithms, scalable interpretation solutions, and curated pharmacogenomics modules and content, all within a secure, HIPAA-compliant analysis environment. Omicia also allows users to generate customizable clinical reports and accommodates various trial sizes and designs.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.